Regencell Bioscience: Dr. Chao Resigns, COO Chung Appointed Director
Ticker: RGC · Form: 6-K · Filed: 2024-01-02T00:00:00.000Z
Sentiment: neutral
Topics: board-change, leadership, corporate-governance
TL;DR
**Regencell Bioscience just swapped out a director, promoting their COO to the board.**
AI Summary
Regencell Bioscience Holdings Limited announced a change in its board of directors. Dr. Yi-Chung Chao resigned as a director for personal reasons, effective December 27, 2023. James Wai Hong Chung, the company's current Chief Operating Officer, was appointed to fill the vacancy on December 28, 2023, and will receive an annual director fee of HK$84,000. This matters to investors because changes in leadership, even for personal reasons, can impact strategic direction and operational stability, though the appointment of an internal COO suggests continuity.
Why It Matters
This filing signals a minor leadership transition at Regencell Bioscience, with an internal promotion ensuring continuity in management and strategic oversight.
Risk Assessment
Risk Level: low — The resignation was for personal reasons and an internal candidate was immediately appointed, suggesting minimal disruption to company operations or strategy.
Analyst Insight
Investors should note the continuity in leadership with an internal promotion, suggesting no immediate strategic shifts. Monitor future filings for any further board changes or strategic announcements.
Key Numbers
- HK$84,000 — Annual Director Fee (The compensation James Wai Hong Chung will receive for his director role.)
- December 27, 2023 — Effective Date of Resignation (When Dr. Yi-Chung Chao's resignation became effective.)
- December 28, 2023 — Effective Date of Appointment (When James Wai Hong Chung was appointed as a director.)
Key Players & Entities
- Dr. Yi-Chung Chao (person) — resigning director of Regencell Bioscience Holdings Limited
- James Wai Hong Chung (person) — appointed director and current Chief Operating Officer of Regencell Bioscience Holdings Limited
- Regencell Bioscience Holdings Limited (company) — the registrant company
- HK$84,000 (dollar_amount) — annual director fee for James Wai Hong Chung
Forward-Looking Statements
- Regencell Bioscience's operational strategy will likely remain consistent due to the internal promotion of the COO to the board. (Regencell Bioscience Holdings Limited) — medium confidence, target: 2024-12-31
FAQ
Who resigned from the board of directors of Regencell Bioscience Holdings Limited?
Dr. Yi-Chung Chao, a director of Regencell Bioscience Holdings Limited, resigned from the board of directors.
What was the effective date of Dr. Yi-Chung Chao's resignation?
Dr. Yi-Chung Chao's resignation was effective December 27, 2023.
Who was appointed to fill the vacancy on the board of directors?
James Wai Hong Chung, the Company's current Chief Operating Officer, was appointed as a director to fill the vacancy.
What is James Wai Hong Chung's current role in addition to being a director?
James Wai Hong Chung will continue to serve as the Company's Chief Operating Officer.
What is the annual director fee for James Wai Hong Chung?
Pursuant to the offer letter signed on December 28, 2023, Mr. Chung will receive an annual director fee of HK$84,000 in cash, payable monthly.
Filing Stats: 439 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2024-01-02 06:04:03
Key Financial Figures
- $84,000 — ill receive an annual director fee of HK$84,000 in cash, payable monthly, and will be r
Filing Documents
- ea190974-6k_regencell.htm (6-K) — 14KB
- ea190974ex10-1_regencell.htm (EX-10.1) — 31KB
- 0001213900-24-000003.txt ( ) — 46KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: January 2, 2024 Regencell Bioscience Holdings Limited By: /s/ Yat-Gai Au Name: Yat-Gai Au Title: Chief Executive Officer and Chairman of the Board of Directors 2